Asenapine restores cognitive flexibility in rats with medial prefrontal cortex lesions.
D000818:Animals; D001927:Brain Diseases / Q000139:chemically induced* / Q000523:psychology*; D001931:Brain Mapping; D003071:Cognition / Q000187:drug effects*; D003986:Dibenzocycloheptenes; D004193:Discrimination Learning / Q000187:drug effects; D018690:Excitatory Amino Acid Agonists; D006576:Heterocyclic Compounds, 4 or More Rings / Q000494:pharmacology*; D007051:Ibotenic Acid; D007150:Immunohistochemistry; D008297:Male; D009474:Neurons / Q000502:physiology; D018697:Nootropic Agents / Q000494:pharmacology*; D009812:Odorants; D016761:Oncogene Proteins v-fos / Q000378:metabolism; D010449:Peptide Mapping; D017397:Prefrontal Cortex / Q000473:pathology / Q000502:physiology*; D011597:Psychomotor Performance / Q000187:drug effects; D051381:Rats
D003986:Dibenzocycloheptenes; D018690:Excitatory Amino Acid Agonists; D006576:Heterocyclic Compounds, 4 or More Rings; D018697:Nootropic Agents; D016761:Oncogene Proteins v-fos; D007051:Ibotenic Acid; C522667:asenapine